BJH - volume 6, issue Abstract Book BHS, january 2015
A. Devresse , S. Daens , R. Lhommel , L. Knoops MD, PhD, D. Bauwens , E. Van den Neste MD, PhD, X. Poiré MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
G. Di Prinzio , C. Cornil , E. Collinge MD, A. Devresse , P.D.M. Katoto , V. Havelange MD, PhD, E. Van den Neste MD, PhD, X. Poiré MD, PhD, M-C. Vekemans MD
BJH - volume 6, issue Abstract Book BHS, january 2015
P.D.M. Katoto , N. Vanlangendonck , V. Havelange MD, PhD, X. Poiré MD, PhD, C. Lambert MD, M-C. Vekemans MD, A. Ferrant , V. Lannoy , E. Van den Neste MD, PhD
BJH - volume 5, issue 3, september 2014
E. Mourin MD, A. Van Hoof MD, PhD, A. Bosly MD, PhD, C. Bonnet MD, PhD, V. De Wilde MD, PhD, C. Doyen MD, PhD, C. Hermans MD, PhD, A. Janssens MD, PhD, L. Michaux MD, PhD, W. Schroyens MD, PhD, A. Sonet MD, E. Van den Neste MD, PhD, G. Verhoef MD, PhD, P. Zachée MD, PhD, M. André MD, PhD
Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of all non-Hodgkin’s lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.2–5
(BELG J HEMATOL 2014;5(3):89–96)
Read moreBJH - volume 5, issue 3, september 2014
P. Mineur MD, F. Hubert , E. Van den Neste MD, PhD, K. Peeters PhD
We observed severe hyponatremia in a patient who was treated with bortezomib for multiple myeloma. The patient was diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone due to bortezomib.
(BELG J HEMATOL 2014;5(3):104–5)
Read moreBJH - volume 5, issue 1, march 2014
D. Bron MD, PhD, E. Van den Neste MD, PhD, A. Kentos MD, PhD, F. Offner MD, PhD, W. Schroyens MD, PhD, C. Bonnet MD, PhD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, A. Janssens MD, PhD
Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal marginal zone lymphoma and splenic marginal zone lymphoma lymphocytes +/− villous lymphocytes. The different diagnosis, work up and treatment options are discussed in these guidelines.
(BELG J HEMATOL 2014;5(1):12–21)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
J. Devreux , G. David , A. Dermine , V. Havelange MD, PhD, B. Ghaye , E. Van den Neste MD, PhD, L. Michaux MD, PhD, X. Poiré MD, PhD, M-C. Vekemans MD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
